1. Conceptual design of cryogenic system for comprehensive research facility for key fusion reactor core systems. (April 2019) Authors: Hu, L; Zhang, Q; Zhu, Z; Lu, X; Zhou, Z; Fu, B; Cheng, A Journal: IOP conference series Issue: Volume 502(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P-238Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy. (2nd July 2019) Authors: Rimassa, L; Cheng, A; Braiteh, F; Benzaghou, F; Hazra, S; Borgman, A; Sinha, R; Kayali, Z; Zhu, A; Kelley, R Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P-187A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection. (2nd July 2019) Authors: Knox, J; Cheng, A; Cleary, S; Galle, P; Kokudo, N; Lencioni, R; Park, J; Zhou, J; Mann, H; Morgan, S; Liu, X; Chin, S; Vlahovic, G; Fan, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P-217A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2. (2nd July 2019) Authors: Knox, J; Cheng, A; Cleary, S; Galle, P; Kokudo, N; Lencioni, R; Park, J; Zhou, J; Mann, H; Morgan, S; Liu, X; Chin, S; Vlahovic, G; Fan, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. O-022Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC). (2nd July 2019) Authors: Miksad, R; Cicin, I; Chen, Y; Klumpen, H; Kim, S; Lin, Z; Youkstetter, J; Sen, S; Cheng, A; Meyer, T; Kelley, R; Abou-Alfa, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 42THE IMPACT OF DEMENTIA ON MORTALITY IN ACUTE MEDICAL ADMISSIONS. (4th September 2018) Authors: Burford, C; Cheng, A; Jayne, M; Alexander, E C; Hall, J; Lee, K K; Patel, A S Journal: Age and ageing Issue: Volume 47(2018)Supplement 3 Page Start: iii14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 40THE RELATIONSHIP BETWEEN LIVING ARRANGEMENT, CARE PACKAGES AND INPATIENT DEATHS IN OLDER ADULTS: A RETROSPECTIVE STUDY AT A LONDON TEACHING HOSPITAL. (4th September 2018) Authors: Cheng, A; Alexander, E C; Burford, C; Jayne, M; Hall, J; Patel, A S; Lee, K K Journal: Age and ageing Issue: Volume 47(2018)Supplement 3 Page Start: iii14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P396Tranexamic acid effectively inhibits fibrinolysis in the presence of anticoagulant and antiplatelet medications. (19th March 2018) Authors: Goodman, J; Worrell, S; Cheng, A; Yuan, C; Seethamraju, K Journal: Europace Issue: Volume 20(2018)Supplement 1 Page Start: i71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P-100Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress. (20th June 2018) Authors: Cheng, A; Abou-Alfa, G; Ren, Z; Assenat, E; Cubillo, A; Pluntke, S; Rimassa, L; Ross, P; Wyrwicz, L; Hou, J; Li, C; Wu, J; Ducreux, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. O-011Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC). (20th June 2018) Authors: Merle, P; Rimassa, L; Ryoo, B; Cicin, I; Harris, W; Banu, E; Sarker, D; Tan, B; Van Vlierberghe, H; Sen, S; Love, C; Cheng, A; Meyer, T; Kelley, R; Abou-Alfa, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗